MRK · News · 20260906N
Melanoma Vaccine Collaboration
Merck & Co., Inc. · 2026-09-06 · Importance 34 · Surprise 42 · In source text
Merck and Moderna reported positive Phase 3 results for a personalized mRNA-based cancer therapy in melanoma, focused on reducing recurrence. The collaboration has driven a significant increase in investor attention to Moderna’s oncology pipeline, with Moderna shares reportedly rising 143% over one month. The development strengthens Merck’s longer-term oncology pipeline beyond Keytruda and supports the partners’ continued clinical and commercial development efforts.
Key facts
- Merck and Moderna announced positive Phase 3 trial results for their mRNA-based cancer therapy in melanoma. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | probable | — | Merck and Moderna announced positive Phase 3 trial results for their mRNA-based cancer therapy in melanoma. |